The Nomination Committee proposes that Jan Ståhlberg is elected new member of the Board and Chairman of Bactiguard Holding AB (publ)
The Nomination Committee of Bactiguard Holding AB (publ) (Bactiguard) proposes that the Annual General Meeting 2018 elects Jan Ståhlberg as new member and Chairman of the Board, as Stanley Brodén who has been the Chairman of the Board since 2015 has declined reelection.
Jan Ståhlberg is Vice Chairman of EQT AB and has been active in EQT since 1995. Earlier in his career, between 1985 and 1994, Jan Ståhlberg worked in various positions at Ovako Steel.
Jan Ståhlberg has extensive experience in board work, both domestically and internationally, including the cancer diagnostic company Dako, Carl Zeiss Vision and Gambro in the life science industry.
Jan Ståhlberg holds a BSc from the Stockholm School of Economics and has studied in the MBA program at the New York University Stern School of Business.
At year-end 2017, Jan Ståhlberg had a total of 1 584 786 B shares in Bactiguard, corresponding to 4.8 percent of the capital and 2.3 percent of the votes, which means that he was the third largest shareholder in the company at the time.
The Nomination Committee's full proposal will be presented in the notice convening the Annual General Meeting 2018 and on the company's website at the same time.
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2018-01-22, at. 08.00
For further information, please contact:
Cecilia Edström, CFO, cell phone: +46 72 226 23 28
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com